BREAKING NEWS

U.S. health regulator approves Teva's migraine drug

By REUTERS

SEPTEMBER 15, 2018 01:29

Israeli drugmaker Teva Pharmaceutical Industries on Friday received approval from the U.S. Food and Drug Administration to sell its new migraine treatment, a key drug the company has been banking on to help revive its fortunes.

The world's largest generic drugmaker had hoped to receive approval for the injectable drug, fremanezumab, by June. Its release was delayed due to U.S. regulatory concerns about the manufacturing process at the South Korean plant of its development partner Celltrion.

Around 39 million Americans suffer from migraine headaches, according to the Migraine Research Foundation, making for a large market that has attracted several drugmakers.

WHO says northern Gaza hospital 'out of service' due to IDF activity

By JERUSALEM POST STAFF

12/28/2024 03:59 AM

Trump to become the first elected politician with two state visits

By REUTERS

12/28/2024 12:21 AM

US intelligence points to misidentification of Azerbaijani plane

By REUTERS

12/27/2024 09:49 PM

Israel reportedly to pursue a broader campaign against Houthis - report

By JERUSALEM POST STAFF

12/27/2024 09:07 PM